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Abstract: Pre-eclampsia (PE) complicates 2%–8% of all pregnancies and is an important 
cause of perinatal morbidity and mortality worldwide. In order to reduce these complications 
and to develop possible treatment modalities, it is important to identify women at risk of 
developing PE. The use of biomarkers in early pregnancy would allow appropriate 
stratification into high and low risk pregnancies for the purpose of defining surveillance in 
pregnancy and to administer interventions. We used formal methods for a systematic  
review and meta-analyses to assess the accuracy of all biomarkers that have been evaluated 
so far during the first and early second trimester of pregnancy to predict PE. We found  
low predictive values using individual biomarkers which included a disintegrin and 
metalloprotease 12 (ADAM-12), inhibin-A, pregnancy associated plasma protein A  
(PAPP-A), placental growth factor (PlGF) and placental protein 13 (PP-13). The pooled 
sensitivity of all single biomarkers was 0.40 (95% CI 0.39–0.41) at a false positive rate of 
10%. The area under the Summary of Receiver Operating Characteristics Curve (SROC) was 
0.786 (SE 0.02). When a combination model was used, the predictive value improved to  
an area under the SROC of 0.893 (SE 0.03). In conclusion, although there are multiple 
potential biomarkers for PE their efficacy has been inconsistent and comparisons are difficult 
because of heterogeneity between different studies. Therefore, there is an urgent need for 
high quality, large-scale multicentre research in biomarkers for PE so that the best predictive 
marker(s) can be identified in order to improve the management of women destined to 
develop PE. 
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1. Introduction 
Pre-eclampsia (PE) is an important cause of perinatal morbidity and mortality and complicates 2%–8% 
of pregnancies [1]. Worldwide, PE is responsible for more than 50,000 maternal deaths annually [2,3]. 
It is characterized by de novo hypertension and proteinuria after 20 weeks of gestation. However, PE 
continues to cause diagnostic dilemmas due to the heterogeneity of its clinical presentations. Clinical 
phenotypes range from early-onset severe hypertension accompanied by fetal growth restriction and its 
consequences to late-onset mild hypertension with a normally grown (or even macrosomic) fetus and 
few long-term complications. The concept that PE may involve several subtypes is now emerging in  
the literature. It is thought that the end clinical presentation may be due to the maternal response to 
abnormal placentation or placental function [4]. 
As PE cannot be predicted by previous obstetric history and risk factors alone [5], much research has 
focused on the identification of women at high risk of developing PE. This would allow more intensive 
monitoring of this high risk group as well as targeted prophylactic intervention, timely diagnosis and 
treatment. The identification of PE biomarkers in early pregnancy would enable appropriate stratification 
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of a pregnancy into high and low risk, such that a positive predictive test would allow specific therapeutic 
interventions. Maternal deaths due to PE might thus be avoided more easily as the ultimate long term 
goal [6]. However, on a pragmatic basis, the identification of PE biomarkers would lead to increased 
maternal surveillance of high risk pregnancies and improve perinatal outcomes. 
Due to the complex pathophysiology and aetiology of PE, a wide range of potential biomarkers have 
been investigated [7]. These biomarkers can be classified under different categories and many novel 
biomolecules have been identified. In addition to the predictive value of biomarkers, the identification 
of these entities (e.g., metabolomic or proteiomic molecules) may elucidate the underlying mechanism 
for the pathogenesis of PE. Although no single biomarker has been deemed suitable for clinical 
application at present [8] various novel biomarkers or combinations of biomarkers with other well 
recognized clinical parameters are promising. To this end, we conducted a systematic review and  
meta-analyses of biomarkers during the first half of pregnancy for the prediction of PE. 
2. Results 
Of the 1716 identified articles, 147 articles were included following full screening. The study 
selection process is illustrated in Figure 1, while the overall result of the QUADAS-2 quality assessment 
is shown in Figure 2. Figure 3 demonstrates the frequency of the different laboratory biomarkers in all 
included studies (401 laboratory biomarkers were described in 147 studies). Placental growth factor 
(PlGF), pregnancy associated plasma protein A (PAPP-A), soluble fms-like tyrosine kinase (sFLT) and 
placental protein 13 (PP-13) were the most commonly studied biomarkers. 
 
Figure 1. Flowchart of selection process. GA: gestational age. 
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Figure 2. QUADAS-2 Quality score. QUADAS: Quality Assessment of Diagnostic 
Accuracy Studies. 
 
Figure 3. Distribution of studied laboratory biomarkers (n = 401) in included articles  
(n = 147). PlGF: Placental growth factor; PAPP-A: Pregnancy associated plasma protein 
A; PP-13: Placental protein 13; ADAM-12: a disintegrin and metalloprotease 12;  
CRP: C-reactive protein; sFlt: Soluble fms-like tyrosine kinase-1; MMP-9: Matrix 
metallopeptidase 9; TNF-R1: Tumour-necrosis factor receptor-1; VEGF: Vascular 
endothelial growth factor; VEGFR: Vascular endothelial growth factor receptor; SHBG: 
Sex hormone-binding globulin. 
We were able to extract sensitivity and specificity from 36 studies for all PE, 10 studies for EOPE 
and 7 studies for LOPE; we performed a meta-analyses of all single biomarkers and of the reported 
combination of biomarkers separately. We performed separate meta-analyses for the following 
biomarkers (>2 studies available): a disintegrin and metalloprotease 12 (ADAM-12), inhibin-A, PAPP-A, 
PlGF, PP-13. The characteristics of the included studies are shown in Table 1. 
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Table 1. General characteristics of the included studies in the meta-analyses. GH: gestational hypertension; SGA: small for gestational age. 
PTB: preterm birth. The outcomes used were in line with the definitions from International Society for the study of Hypertension (ISSHP) [9]. 
Study Year GA of Test (Weeks) Biomarker (s) Outcome Study Design A Low/High Risk Location n (Total) n (PE) 
Level of 
Evidence 
Anderson et al. [10] 2011 11–16 
α-1-microglobulin  
and fetal hemoglobin 
PE 
Nested case control  
(in prospective study) 1 
LR UK 96 60 3b 
Akolekar et al. [11] 2008 11–14 PlGF, PAPP-A EOPE, LOPE, GH 
Nested case-control (in trisomy 
21 screening cohort) 2 
LR + HR UK 824 127 3b 
Akolekar et al. [12] 2013 11–14 PlGF, PAPP-A PE 
Prospective cohort  
(in screening) 
LR + HR UK 58,703 1245 1b 
Audibert et al. [13] 2010 11–13 
PAPP-A, ADAM-12, PlGF, 
hCG, inhibin-A, PP-13, 
protein-A, inhibin-A 
PE, EOPE,  
LOPE, GH 
Prospective cohort  
(trisomy 21 screening cohort) 3 
LR + HR Canada 893 40 1b 
Bills et al. [14] 2009 First trimester VEGF(165)b, sFLT, sEng PE, EOPE, LOPE Case-control 4 LR + HR UK 70 25 3b 
Bosio et al. [15] 2001 10–14 P-selectin PE, GH 
Nested case-control  
(in longitudinal cohort) 5 
LR + HR Ireland 70 20 3b 
Boucoiran et al. (1) [16] 2013 12–18 PlGF, sFlt-1, inhibin A PE, GH, SGA 
Prospective cohort  
(nested in RCT) 6 
LR + HR Canada 793 34 1b 
Boucoiran et al. (2) [17] 2013 11-14 and 18-22 PlGF, PP-13, ADAM-12 EOPE, LOPE, GH 
Prospective cohort  
(trisomy 21 screening cohort) 7 
LR + HR Canada 893 40 1b 
Brameld et al. [18] 2008 12 + 3 PAPP-A, free-hCG PE 
Retrospective cohort  
(trisomy 21 screening cohort) 8 
LR Australia 22,125 660 2b 
Chafetz et al. [19] 2007 9–12 PP-13 PE, PTB, SGA 
Nested case control in 
prospective cohort  
(MOMS-study) 9 
LR USA 425 47 3b 
Cohen et al. [20] 2014 10–13 
PAPP-A, α fetoprotein,  
free β-hCG 
PE 
Nested case control  
(retrospective cohort) 10 
LR + HR USA 2199 148 3b 
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Table 1. Cont. 
Study Year GA of Test (Weeks) Biomarker (s) Outcome Study Design A Low/High Risk Location n (Total) n (PE) 
Level of 
Evidence 
Cowans et al. [21] 2011 11–14 PP-13 EOPE, LOPE 
Nested case control (in cohort 
of trisomy screening) 11 
HR UK 234 37 3b 
Deurloo et al. [22] 2013 9–14 ADAM-12, PP-13 PE, GH, SGA 
Nested case control (in cohort 
of trisomy screening 12 
LR + HR The Netherlands 220 17 3b 
Dugoff et al. [23] 2004 10–14 PAPP-A PE, PTB, SGA 
Prospective study (FASTER 
trial, trisomy screening cohort) 13 
LR USA 34,271 764 1b 
Giguere et al. [24] 2014 10–18 
PlGF, sFlt, PAPP-A, 
inhibin-A 
PE 
Nested case-control  
(in prospective cohort) 14 
LR Canada 648 216 3b 
Goetzinger et al. [25] 2013 11–14 ADAM-12, PAPP-A PE, EOPE, LOPE Prospective cohort 15 LR + HR USA 578 54 1b 
Gonen et al. [26] 2008 6–10 PP-13 PE, GH Prospective cohort 16 LR + HR Israel 1239 20 1b 
Ghosh et al. [27] 2013 11–14 PlGF EOPE 
Prospective study  
(screening antenatal care) 17 
LR + HR India 1206 9 1b 
Hedley et al. [28] 2010 10–14 PAPP-A, free leptin index PE 
Nested case control (in First 
Trimester Screening Study) 18 
LR Denmark 415 126 3b 
Kang et al. [29] 2008 11 and 16 
PAPP-A, AFP, uE3, hCG, 
inhibin-A 
PE 
Retrospective cohort (trisomy 
21 screening cohort) 19 
LR + HR Korea 3076 32 2b 
Kenny et al. [30] 2014 14–16 Multiple 
PE, EOPE, preterm 
and term PE 
Prospective cohort 20 LR 
Australia/ 
UK/Ireland 
5623 278 1b 
Khalil et al. [31] 2010 11–14 PP-13 
PE, EOPE,  
PE + SGA 
Nested case-control  
(in antenatal clinic cohort) 21 
HR UK 252 42 3b 
Kuc et al. [32] 2013 9–14 
PAPP-A, free -hCG, 
ADAM-12, PlGF 
EOPE, LOPE 
Nested case control  
(in screening cohort) 22 
LR + HR The Netherlands 667 167 3b 
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Table 1. Cont. 
Study Year GA of Test (weeks) Biomarker (s) Outcome Study Design A Low/High Risk Location n (Total) n (PE) 
Level of 
Evidence 
Kusanovic et al. [33] 2009 6–15 
PlGF, soluble endoglin, 
sVEGFR-1 
EOPE, LOPE Prospective cohort 23 LR Chile 1622 62 3b 
Myatt et al. [34] 2012 9–13 
ADAM-12, PAPP-A,  
PP-13, sFLT, endoglin 
PE 
Nested case control  
(in cohort of RCT) 24 
LR USA 683 174 2b 
Myers et al. [35] 2013 14–16  
PlGF, soluble endoglin, 
sFLT-1 
preterm PE  
(<37 week) 
Prospective cohort 25 LR 
Australia/UK/ 
Ireland 
235 47 1b 
Nicolaides et al. [36] 2006 11–14 PP-13 EOPE 
Nested case control  
(in screening cohort) 26 
LR + HR UK 433 10 3b 
Odibo et al. [37] 2011 11–14 PP13, PAPP-A PE, EOPE 
Prospective cohort (trisomy  
21 screening cohort) 27 
LR + HR USA 452 42 1b 
Park et al. [38] 2014 11–14 
PAPP-A, PlGF, inhibin-A, 
sFLT 
LOPE Prospective cohort 28 LR Korea 262 8 1b 
Poon et al. (1) [39] 2009 11–14 PAPP-A PE, EOPE, LOPE 
Prospective cohort (trisomy  
21 screening cohort) 29 
LR + HR UK 8051 156 1b 
Poon et al. (2) [40] 2009 11–14 
PAPP-A, MMP-9,  
TNF-R1 
EOPE, LOPE, 
GH, SGA, PTB 
Nested case-control (in trisomy 
21 screening cohort) 30 
LR + HR UK 1138 128 3b 
Roes et al. [41] 2004 6–15 Inhibin-A PE Case control 31 LR The Netherlands 55 19 3b 
Schneuer et al. [42] 2012 11–13 PP-13 
PE, EOPE,  
LOPE, SGA 
Prospective cohort (trisomy  
21 screening cohort) 32 
LR + HR Australia 2678 71 1b 
Spencer et al. [43] 2006 11–14 PP-13, PAPP-A PE, EOPE, LOPE 
Nested case-control (in trisomy 
21 screening cohort) 33 
LR UK 534 88 3b 
Spencer et al. [44] 2008 11–14 Inhibin-A and activin-A PE, EOPE, LOPE 
Nested case-control (in trisomy 
21 screening cohort) 34 
LR UK 304 64 3b 
Tidwell et al. [45] 2001 5–15 PlGF EOPE, LOPE Case control 35 LR Taiwan 39 14 3b 
  
Int. J. Mol. Sci. 2015, 16 23042 
 
 
Table 1. Cont. 
Study Year GA of Test (Weeks) Biomarker (s) Outcome Study Design A Low/High Risk Location n (Total) n (PE) 
Level of 
Evidence 
Thilaganathan et al. [46] 2010 14.7 (CO), 16.3 (PE) cystatin-C, CRP PE 
Nested case-control  
(in antenatal clinic cohort) 36 
LR UK 170 45 3b 
Xu et al. [47] 2014 First trimester Chemerin PE 
Prospective cohort  
(antenatal care)37 
LR China 518 41 1b 
Youssef et al. [48] 2011 11–14 
PAPP-A, PlGF, sFlt-1,  
P-selectin, NGAL 
LOPE Prospective cohort 38 LR + HR Italy 528 13 1b 
Yu et al. [49] 2011 12–16 
PlGF, inhibin-A,  
activin-A 
PE 
Nested case-control  
(in antenatal clinic cohort) 39 
LR China 124 31 3b 
Zong et al. [50] 2012 13–16 
Htr-A1  
(High-Temperature 
Requirement A1) 
PE 
Prospective cohort  
(clinical cohort) 40 
LR China 1396 100 1b 
A Characteristics of the study population are mentioned below; 1 Exclusion criteria diabetes, prepregnancy hypertension and premature delivery; 2 Controls: did not  
develop any pregnancy complications and resulted in the live birth of phenotypically normal neonates; 3 Exclusion: multiparous, multiple gestation, major fetal 
chromosomal/structural anomaly; 4 Exclusion: pregnancy induced hypertension, fetal growth restriction, intrauterine death, preterm birth (PTB); 5 Controls: normal obstetric 
outcome. Matched for body mass index (BMI); 6 Exclusion: vitamin C and/or vitamin E supplements, history of major medical complications, major fetal defects, repeated 
spontaneous abortion, use of an illicit drug or warfarin treatment during the current pregnancy; 7 Inclusion: nulliparous women with singleton pregnancies without major 
fetal chromosomal or structural anomaly; 8 Exclusion: Women who had a previous fetus with a chromosomal abnormality and women with insulin-dependent diabetes 
mellitus; 9 Exclusion: AIDS or hepatitis, cases of major fetal anomaly, fetal death and women with placenta previa, placenta accrete, or placental abruption; 10 General 
population, singleton pregnancies; 11 A priori high risk pregnancies; 12 General population; 13 Inclusion: singleton pregnancy, exclusion: diabetes and chromosomal 
abnormalities;. 14 Exclusion: chronic hepatic or renal diseases, pregnancies with major fetal abnormalities and those ending in termination, miscarriage or fetal death  
<24 weeks; 15 Exclusion : known aneuploidy and major congenital malformations; 16 Exclusion: miscarriages; 17 Exclusion: congenital abnormalities or medication use;  
18 Randomly selected controls; 19 Exclusion: multifetal gestation, diabetes, chromosomal or structural abnormalities; 20 Exclusion: increased risk factors of PE, SGA or PTB, 
known major fetal anomaly or abnormal karyotype, intervention that may modify pregnancy outcome such as treatment with aspirin or progesterone; 21 Inclusion: history of 
PE in a previous pregnancy, chronic hypertension, chronic renal disease, antiphospholipid syndrome, systemic lupus erythematosus, pregestational diabetes mellitus, obesity 
(BMI ≥ 30 kg/m2). Exclusion: multiple pregnancy, cases of major fetal anomaly, miscarriage or fetal death, HIV or hepatitis, placenta previa or placental abruption;  
22 Exclusion: multiple pregnancy, delivery <24 weeks, chromosomal abnormalities; 23 Inclusion: pregnancies in which a single live fetus was delivered after 37 complete 
weeks of gestation with birth weight above the 10th centile and without fetal anomalies; 24 Inclusion: nulliparous, low risk women; 25 Exclusion: increased risk of PE, SGA 
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or PTB, known major fetal anomaly or abnormal karyotype, intervention that may modify pregnancy outcome such as treatment with aspirin or progesterone; 26 Gestational 
age matched controls; 27 Inclusion : singleton pregnancies. Exclusion: spontaneous miscarriage prior to 20 weeks, loss to follow-up or fetal anomalies diagnosed in the 
second trimester; 28 Exclusion: high risk pregnancies; 29 Definition controls: randomly selected women without reported pregnancy-associated hypertension; 30 Definition 
controls: had blood collected and stored on the same day, which did not develop any pregnancy complications and resulted in the live birth of phenotypically normal neonates; 
31 Unknown in- and exclusion criteria; 32 Inclusion: singleton pregnancies; 33,34 Gestational age matched controls; 35 Exclusion: multiparity, chronic hypertension, diabetes, 
multiple gestation, connective tissue disorder, any long-term use of medicine other than prenatal vitamins, and miscarriage before viability;. 36 Exclusion: diabetes, connective 
tissue disease, renal disorders, essential hypertension; 37 Exclusion: previous systemic disorders or drug use, chronic hypertension, diabetes, renal disorders, recent or present 
fever or infectious disease, malignancies, autoimmune diseases and multiple pregnancies; 38 Exclusion: early-onset PE, multiple gestations, pregnancies with fetal 
chromosomal or major structural anomaly, miscarriages; 39 Unknown inclusion/exclusion criteria; 40 Exclusion: cases showing intrahepatic cholestasis of pregnancy, abortion, 
peripartum cardiomyopathy, and other complications. PlGF: Placental growth factor; PAPP-A: Pregnancy associated plasma protein A; ADAM-12: A disintegrin and 
metalloprotease 12; CRP: C-reactive protein; hCG: human chorionic gonadotropin; PP-13: Placental protein 13; VEGF: Vascular endothelial growth factor; sFLT: Soluble 
fms-like tyrosine kinase-1; sEng: Soluble endoglin; sVEGR-1: Soluble endothelial growth factor-1; uE3: Oestradiol; MMP-9: Matrix metallopeptidase 9; TNF-R1:  
Tumor-necrosis factor receptor-1; NGAL: Neutrophil gelatinase-associated lipocalin; (1): publication 1 by same author in same year; (2): publication 2 by same author in 
same year. 
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2.1. PE 
In studies which analysed women with PE without sub-classifying into EOPE and LOPE, the pooled 
sensitivity of all single biomarkers (n = 66) was 0.40 (95% CI 0.39–0.41, I2 96.9%) at a false positive 
rate of 10% (Figure 4). The area under the SROC was 0.786 (SE 0.02) (Figure 5). The pooled sensitivity, 
specificity and area under the SROC of the separate meta-analyses of ADAM-12, inhibin-A, PAPP-A, 
PlGF and PP-13 are shown in Table 2. All these meta-analyses showed a high heterogeneity (I2 > 50%). 
 
Figure 4. Meta-analysis of single laboratory biomarkers in PE (both EOPE and LOPE). Legend: 
(1) activin-A; (2) ADAM-12; (3) α fetoprotein; (4) α-1-macroglobulin; (5) anti-CD63 (GP53, 
lysosomal secretion); (6) chemerin; (7) C-reactive protein; (8) cystatin C; (9) endoglin;  
(10) E-selectin; (11) fetal DNA; (12) fetal hemoglobin (ratio); (13) fibronectin; (14) free β-hCG; 
(15) free leptin index; (16) GRP78 (glucose regulated protein) ratio C-term/full length;  
(17) Htr-A1 (High-Temperature Requirement A1); (18) inhibin-A; (19) NGAL (neutrophil 
gelatinase-associated lipocalin); (20) PAPP-A; (21) PBMC (peripheral blood mononuclear 
cell) miRNA; (22) PlGF; (23) PP-13; (24) P-selectin; (25) soluble endoglin; (26) sFLT/PlGF 
ratio; (27) sFlt-1; (28) sVEGFR-1 (vascular endothelial growth factor); (29) TNF-R1 (tumor 
necrosis factor receptor). PE: Pre-eclampsia; EOPE: early-onset PE; LOPE: late-onset PE. 
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Figure 5. Summary of receiver operating characteristics curve of single laboratory 
biomarkers in PE (both EOPE and LOPE). 
2.2. Early-Onset PE 
In the group of studies which categorized EOPE separately (n = 17), the pooled sensitivity of all 
single biomarkers was 0.37 (95% CI 0.32–0.41, I2 82.4%) with a specificity of 0.88 (95% CI 0.87–088, 
I2 98.8%). The area under the SROC was 0.794 (SE 0.05). The pooled sensitivity, specificity and area 
under the SROC of the separate meta-analyses of PAPP-A, PlGF and PP-13 are shown in Table 2. 
2.3. Late-Onset PE 
In late-onset PE, (n = 14), the pooled sensitivity of all single biomarkers was 0.22 (95% CI 0.19–0.25,  
I2 82.2%) with a specificity of 0.89 (95% CI 0.88–089, I2 97.4%). The area under the SROC was 0.763  
(SE 0.106). The pooled sensitivity, specificity and area under the SROC of the separate meta-analyses 
of PAPP-A is shown in Table 2. 
2.4. Combination of Biomarkers 
From 13 studies, we extracted a pooled sensitivity of 0.43 (95% CI 0.41–0.46, I2 95.8) and a pooled 
sensitivity of 0.91 (95% CI 0.90–0.91, I2 98.3) and an area under the SROC of 0.893 (SE 0.03) for  
a combination model of clinical characteristics, laboratory biomarkers and/or uterine artery Doppler 
pulsatility index (UA-PI). The forest plot and SROC of these studies are shown in Figures 6 and 7, respectively. 
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Figure 6. Meta-analysis of combination of laboratory and clinical makers in PE (both EOPE 
and LOPE). Legend: (1) PAPP-A, AFP, uE3, hCG (total or free β), inhibin-A; (2) mean  
PI + activin-A; (3) PlGF/sEng-ratio; (4) PAPP-A and free leptin index; (5) PP-13, UA-PI, 
AIx-75 (measure of arterial stiffness); (6) cystatin-C, CRP, uterine artery resistance index;  
(7) HbF ratio and A1M; (8) activin-A, inhibin-A, PlGF and UA-PI; (9) African American race, 
systolic blood pressure, BMI, education level, ADAM12, PAPP-A, PlGF; (10) BMI, education 
mother and HtrA1; (11) maternal characteristics, PlGF; (12) maternal characteristics, ADAM12; 
(13) maternal characteristics, PlGF; (14) sFLT-1, PlGF, PAPP-A, inhibin A, BMI, MAP;  
(15) PlGF, MAP, BMI, high fruit intake, uterine artery Doppler resistive index (UA-RI) * 
validation cohort; (16) PlGF, MAP, BMI, high fruit intake, UA-RI * training cohort. 
 
Figure 7. Summary of receiver operating characteristics curve of combination model of 
laboratory and makers in PE (both EOPE and LOPE). 
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Table 2. Meta-analyses of single laboratory biomarkers. 
All PE 
Pooled Sensitivity 
(95% CI) 
Pooled Specificity  
(95% CI) 
Area Under 
SROC (SE) 
EOPE 
Pooled Sensitivity 
(95% CI) 
Pooled Specificity 
(95% CI) 
Area Under 
SROC (SE) 
LOPE 
Pooled Sensitivity 
(95% CI) 
Pooled Specificity 
(95% CI) 
Area Under 
SROC (SE) 
ADAM-12 
(n = 3) 
0.26 (021–0.32) 0.84 (0.82–0.86) 0.671 (0.093) 
ADAM-12 
(n = 3) 
- - - - - - - 
Inhibin-A 
(n = 5) 
0.32 (0.25–0.39) 0.90 (0.89–0.91) 0.957 (0.046) 
Inhibin-A 
(n = 5) 
- - - - - - - 
PAPP-A  
(n = 14)  
0.30 (0.29–0.32) 0.92 (0.92–0.92) 0.744 (0.071) 
PAPP-A  
(n = 4)  
0.26 (0.19–0.34) 0.90 (0.89–0.90) 
0.907 
(0.150) 
PAPP-A 
(n = 4) 
0.19 (0.14–0.24) 0.89 (0.89–0.90) 
0.781 
(0.173) 
PlGF  
(n = 8) 
0.65 (0.63–0.67) 0.89 (0.89–0.89) 0.849 (0.068) 
PlGF  
(n = 3) 
0.37 (0.27–0.48) 0.79 (0.78–0.81) 
0.796 
(0.179) 
- - - - 
PP-13  
(n = 9) 
0.37 (0.33–0.41) 0.88 (0.87-0.89) 0.882 (0.0450) 
PP-13  
(n = 9) 
0.59 (0.48–0.69) 0.92 (0.91–0.93) 
0.898 
(0.064) 
- - - - 
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3. Discussion 
There is extensive literature on biomarkers in relation to PE and despite our focused strategy, we 
identified 401 biomarkers from the included publications. We then conducted a systematic review and 
meta-analyses using studies where we were able to extract comparable data for AUC and with more  
than two studies for each biomarker. 
We examined single biomarkers in research conducted with different study cohorts, i.e., EOPE, LOPE 
or PE in general. Five biomarkers were highlighted: ADAM-12, inhibin-A, PAPP-A, PlGF and PP-13. 
ADAM12 is part of the ADAM protein family, which are involved in cell-to-cell and cell-to-matrix 
interactions in neural and muscle development as well as fertilization [51–53]. PAPP-A is part of  
the first trimester Down’s syndrome screening test and is a large zinc glycoprotein produced by placental 
trophoblasts [54]. PlGF and sFLT are both angiogenic factors. PlGF is a polypeptide growth factor 
mainly expressed in placental trophoblasts and regulate the early development of placental villi [55] 
while sFLT induces endothelial cell dysfunction [56]. 
Prediction models utilizing a combination of biomarkers and clinical parameters improved  
the predictive value in studies examining PE (without distinction of EOPE and LOPE) with an area  
under the SROC of 0.893. However, the majority of combined models include evaluation of clinical 
history or assessment of uterine artery Doppler waveforms. This limits the potential of solely using  
laboratory-based biomarkers. 
A limitation of this study is that our search strategy lead to significant number of missed articles that 
were found subsequently by other means, such as through the reference lists of articles that have been 
already identified. This may be due to our limited search terms and the wide variation in terminology 
used for studies on PE. Previous meta-analyses on early pregnancy biomarkers for PE have concentrated 
on either biochemical markers alone [42] or in combination with ultrasound indices [57–59]. 
Due to the low population prevalence of PE, despite >200 studies on candidate biomarkers in  
the literature, none (nor any combination) have been identified with specificity and sensitivity that are 
useful for clinical practice [60]. The systematic review from the World Health Organization (WHO) 
concluded that there is no cost effective or reliable screening test (clinical, biophysical, or biochemical) 
for PE [61]. Perhaps this finding reflects that different types of biomarkers could point to different 
preventative strategies. For example, pregnancies associated with raised ADAM levels may need to be 
treated with aspirin, while those linked to raised PlGF levels may need to be treated with calcium. 
The low predictive values using a single biomarker may be due to the heterogeneity between most 
studies such that we were unable to extract comparable data. Despite using the International Society for 
the study of Hypertension (ISSHP) definition in our review, there is a wide variation in the clinical 
manifestations and categorization of PE, such as early or late gestation, maternal or placental disease 
and mild or severe degree of PE. These could have introduced additional variability between the studies. 
Furthermore, many studies were conducted using different biomarkers, study population and definition 
of PE phenotype, i.e., EOPE, LOPE or PE as one entity. We identified 147 articles but only 36 of  
these could be included in the meta-analyses. For each biomarker analyzed, the number of studies was 
even lower. 
Many publications used PE, without sub-classification into EOPE and LOPE. This resulted in a poorly 
defined phenotype of PE which may further contribute to the low predictive value in these studies.  
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As EOPE and LOPE have distinct and different pathogenesis mechanisms, it is likely that they are 
characterized by different biomarkers. Therefore, it is important to stratify study populations appropriately 
for accurate identification of biomarkers. 
A possible source of bias arises from the over-representation of case-control studies in the reviewed 
literature. Furthermore, some studies were only conducted in women at high-risk of developing PE. 
Biomarkers which only have a high predictive value in EOPE may be another cause of overestimation. 
On the other hand, it is difficult to conduct studies focusing on LOPE as the phenotype is generally less 
severe than EOPE. 
A well-designed study for biomarkers to predict PE in early pregnancy should be conducted in clearly 
defined populations, such as those with EOPE. The classic WHO screening criteria by Wilson and 
Jungner [62] can be adapted for biomarker studies [63,64]. These include: clearly defined clinical 
population and setting for use, set inclusion and/or exclusion criteria, focused outcome of interest, 
prospective specimen collection, aim for positive biomarker results in case and negative biomarker 
results in control, random selection of case and control subjects, accurate definition of true positive and 
true negative rates, clinically acceptable minimal test performance, favourable comparison with current 
risk stratification strategy, defined procedures for sample collection, processing, storage and retrieval, 
blind sampling, consideration of null hypothesis and alternative hypotheses, adequate sample size and 
that there is a policy present for early termination of the study if appropriate.Identification of women at 
risk of PE pre-eclampsia is the first step to effective intervention and prevention. However, currently 
there are no reliable biomarker tests for PE that have been accepted for wide clinical use and some 
countries have banned the use of biomarker screening in early gestation due to the possibility of 
inaccurate predictive test and its ethical implications. It is vital to develop a screening tool which is 
clinically relevant due to the serious consequences of incorrect risk stratification and inappropriate 
medication or pregnancy surveillance. 
4. Methods 
4.1. Studies 
We searched MEDLINE, EMBASE, Cochrane and ISI web of science from inception to 31st January 
2015 using a combination of search terms with synonyms related to pre-eclampsia (“preeclampsia”,  
“pre-eclampsia”, “EPH”, “pregnancy toxemia”, “edema-proteinura-hypertension gestos”, “PE”), 
biomarkers (“biological markers”, “biomarker”, “biological markers”, “laboratory markers”, 
“proteomics”, “metabolomics”, “surrogate endpoint”, “surrogate end point”), and first trimester pregnancy 
(“early pregnancy”, “first trimester pregnancy”, “pregnancy trimester, first”, “first pregnancy trimester”, 
“first trimester”, “early placental phase”). There were no limitations made on publication date or patient 
sample size. We excluded publications which were not in English. Animal studies were not included. 
4.2. Study Selection 
Two independent reviewers (Pensée Wu and Caroline van den Berg) screened the title, abstract and 
key words of each article and made a record of the study design, biomarker type, and test period  
during pregnancy and study outcome. We included observational studies (cohort, cross-sectional and  
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case-control) which assessed tests performed in the first or early second trimester of pregnancy  
for predicting pre-eclampsia in unselected women. The outcome definitions were as described in  
the definition of PE from International Society for the study of Hypertension in Pregnancy (ISSHP).[9] 
Comments, editorials, case series (as defined by the authors of the studies) or reports were excluded, as 
were biomarker tests performed after 20 weeks of gestation. Genetic markers were not included as they 
require a different methodological approach and meta-analytic techniques. Reviews were included in  
the original search, to check for additional references. 
4.3. Quality Assessment 
An adapted version of the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool 
was used to determine the methodological quality of the selected studies as not all items of the tools 
were relevant to our review [65,66]. Summary scores were not calculated as their interpretation is 
difficult and may be potentially misleading [67]. 
4.4. Data Extraction and Synthesis 
We extracted the study outcome measures which were shown in the articles (odds ratio, risk ratio, 
area under the curve (AUC), sensitivity and specificity). In multiple or duplicate publication of the same 
data set, we used the most complete or the most recent study. To perform the meta-analyses we only 
used studies where a sensitivity and specificity was reported. We performed these meta-analyses 
separately for the three different outcomes: PE, early-onset PE (EOPE, before 34 weeks of gestation) 
and late-onset PE (LOPE, after 34 weeks of gestation). Studies that used biomarkers in combination with 
clinical parameters were analyzed separately. 
Meta-DiSc (version 1.4; Zamora et al., Madrid, Spain) [68] was used for statistical analyses. A pooled 
sensitivity and specificity was calculated, as well as a Summary of Receiver Operating Characteristics 
Curve (SROC). Raw data were used from each study, as adjustments for confounding effects varied 
between different studies. The inverse variance of the study was used to determine the weighting of 
studies in the meta-analyses. The random effects model was chosen due to the expected clinical and 
statistical heterogeneity among the studies. We assessed the heterogeneity of the results among studies 
through visual examination of Forest plots of AUC’s, and using the I2 test [69]. For all effect estimates, 
a value of p < 0.05 was considered to be statistically significant. 
5. Conclusions 
We found that PlGF was best at predicting EOPE as a single biomarker. However, a combination 
model performed better than a single biomarker if studying PE as a single entity. A combination model 
including clinical and uterine artery Doppler assessments, negates the attraction of using a laboratory-based 
biomarker(s) prediction strategy. 
Despite multiple potential biomarkers for PE, the efficacy of these markers has been inconsistent 
between different studies. The IMPROvED (IMproved PRegnancy Outcomes by Early Detection) study 
is an international multicentre study screening 5000 women in five European countries with the aim of 
developing a clinically robust predictive blood test for PE, utilising novel metabolite and protein 
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biomarkers [60]. We hope our study will contribute towards the ultimate goal of identifying the best 
predictive marker(s) and improve the management of women destined to develop PE. 
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